Key Developments: Mylan Inc (MYL.O)

MYL.O on Nasdaq

50.20USD
11 Jul 2014
Price Change (% chg)

$-0.50 (-1.00%)
Prev Close
$50.71
Open
$50.62
Day's High
$50.80
Day's Low
$49.95
Volume
2,647,473
Avg. Vol
4,054,637
52-wk High
$57.52
52-wk Low
$31.51

Search Stocks

Latest Key Developments (Source: Significant Developments)

Mylan Inc reaffirms Q2 2014 EPS guidance
Tuesday, 1 Jul 2014 01:03pm EDT 

Mylan Inc:Expects Q2 2014 adjusted diluted earnings per share in the range of $0.67 to $0.70.Q2 2014 EPS of $0.67 - Thomson Reuters I/B/E/S.  Full Article

Mylan Inc launches generic Paraplatin Injection
Monday, 9 Jun 2014 07:30am EDT 

Mylan Inc:Has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin Injection.It is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents.  Full Article

Mylan Inc gives long term EPS guidance - Conference call
Wednesday, 14 May 2014 02:20pm EDT 

Mylan Inc:Says that it has laid out five-year roadmap that takes its EPS to $6, and doubling the size of company by FY 2018.FY 2014 EPS of $3.40, FY 2015 EPS of $3.90, FY 2016 EPS of $4.24, FY 2017 EPS of $4.35, FY 2018 EPS of $4.81 - Thomson Reuters I/B/E/S.  Full Article

Mylan Inc launches generic Zyprexa Zydis tablets
Wednesday, 14 May 2014 07:30am EDT 

Mylan Inc:Launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Co's Zyprexa ZydisTablets.  Full Article

Mylan Inc reaffirms FY 2014 EPS outlook
Thursday, 1 May 2014 07:03am EDT 

Mylan Inc:Reaffirms FY 2014 adjusted diluted EPS guidance range of $3.25 to $3.60.FY 2014 EPS of $3.44 - Thomson Reuters I/B/E/S.  Full Article

Meda rejects revised proposal from Mylan Inc-DJ
Monday, 28 Apr 2014 03:57am EDT 

Meda AB:Rejects a revised offer for the company from Mylan Inc-DJ.Says all continued discussions between Meda and Mylan have been terminated without further actions.Prefers to remain a stand-alone company, while a lack of support from its largest shareholder would make it impossible to complete the transaction anyway.  Full Article

Prosonix and Mylan Inc enter into global licensing agreement for generic versions of inhaled respiratory products flixotide and Flovent
Tuesday, 15 Apr 2014 08:00am EDT 

Prosonix:Says it has entered into a global licensing agreement with Mylan Inc, for its inhaled respiratory products, PSX1001 and PSX1050.Under the terms of the licensing agreement, Prosonix will file PSX1001 in the EU and retain marketing rights in certain territories.Mylan has marketing rights for PSX1001 and PSX1050 in the U.S., Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation and the Commonwealth of Independent States.All other terms of the agreement remain confidential.  Full Article

Actavis plc enters into an agreement with Mylan Inc. and Famy Care Ltd to settle patent litigation
Tuesday, 15 Apr 2014 08:00am EDT 

Actavis plc:Enters into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015.Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on Oct. 1, 2015.Other terms of the settlement were not disclosed.  Full Article

Federal Judge enforces settlement agreement between Mylan Inc and Endo Pharmaceuticals generic FROVA
Friday, 11 Apr 2014 07:30am EDT 

Mylan Inc:Confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an ANDA with the USFDA for Frovatriptan Succinate Tablets, 2.5 mg.The Court has vacated its Jan. 28, decision in favor of Endo regarding the parties' patent litigation over this product, which could have prevented Mylan from launching its generic version of FROVA until after the expiration of U.S. Patent 5,464,864 patent on Nov. 7, 2015.By enforcing the settlement, Mylan can launch its product pursuant to the terms of the settlement, contingent upon final FDA approval.  Full Article

Meda rejects Mylan proposal to combine businesses
Friday, 4 Apr 2014 09:00am EDT 

Meda AB:Confirms has been contacted by Mylan, Inc. regarding an indicative proposal to combine the two businesses.Has decided to reject the proposal.Says all continued discussions between Meda and Mylan have been terminated without further actions.  Full Article

Photo

Exclusive: Mylan near multibillion-dollar deal for Abbott drug assets - sources

NEW YORK - U.S. generic drugmaker Mylan Inc is in advanced talks to acquire a multibillion-dollar portfolio of established products from Abbott Laboratories, people familiar with the matter said.

Search Stocks